GlassScriptPhysician profile
Sameer Saleem
NPI 1215389903
$8,689.06
in general payments reported to CMS, 2019-2025
44 companies · $2,149 in 2025
The $2,149 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $315 · 2021: $553 · 2022: $3,685 · 2023: $592 · 2024: $962 · 2025: $2,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,637 · Travel and Lodging: $1,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,636.95 |
| Travel and Lodging | $1,066.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,012.97 | 2022-2025 | Versacross Access Solution, Cds - Mct/Cem Monitoring, Bodyguardian |
| Abiomed | $753.01 | 2019-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $631.60 | 2019-2025 | Lifevest |
| Amgen INC. | $461.92 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $324.21 | 2019-2024 | Xarelto |
| Pfizer INC. | $238.92 | 2022-2025 | |
| Chiesi USA, INC. | $189.93 | 2019-2025 | Kengreal, Cleviprex |
| E.R. Squibb & Sons, L.L.C. | $188.17 | 2025 | Eliquis, Camzyos |
| Philips North America LLC | $183.35 | 2020-2024 | (Ck4) Mcot |
| Actelion Pharmaceuticals US, INC. | $154.93 | 2023-2024 | Opsumit, Uptravi |
| Penumbra, INC. | $149.65 | 2024 | Indigo System |
| Medtronic, INC. | $148.75 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $141.78 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $122.99 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $108.72 | 2020-2024 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.28 | 2020-2025 | Ofev |
| Alnylam Pharmaceuticals INC. | $67.67 | 2022-2025 | Onpattro, Amvuttra |
| Grifols USA, LLC | $57.83 | 2021-2023 | Prolastin-C Liquid |
| Terumo Medical Corporation | $53.00 | 2022 | |
| Heartflow, INC. | $50.05 | 2025 | |
| Stryker Corporation | $48.88 | 2025 | Flowtriever |
| Abbott Laboratories | $42.49 | 2022 | |
| Shockwave Medical, INC | $40.37 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Baxter Healthcare | $39.08 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Amarin Pharma, INC. | $39.00 | 2019-2021 | |
| Novo Nordisk INC | $31.95 | 2021-2024 | Ozempic, Rybelsus |
| Viatris Specialty LLC | $31.70 | 2025 | Yupelri |
| Inari Medical, INC. | $30.01 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amryt Pharma Holdings LTD | $23.56 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $23.21 | 2024 | Arcalyst |
| Atricure, INC. | $21.89 | 2022 | |
| Mallinckrodt Hospital Products INC. | $20.78 | 2021 | |
| Thrombolex, INC. | $19.07 | 2025 | Bashir Endovascular Catheter |
| Livanova USA, INC. | $18.46 | 2023 | Lifesparc |
| Kowa Pharmaceuticals America, INC. | $18.25 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $16.99 | 2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $15.37 | 2025 | |
| Mayne Pharma Commercial LLC | $15.37 | 2019 | |
| Akcea Therapeutics, INC. | $13.44 | 2020 | |
| Shire North American Group INC | $13.24 | 2019 | |
| Cvrx, INC. | $13.07 | 2023 | Barostim Neo System |
| Siemens Medical Solutions USA, INC. | $12.82 | 2020 | |
| Lundbeck LLC | $12.47 | 2020 | |
| Mylan Specialty L.P. | $11.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Saleem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.